Please provide your email address to receive an email when new articles are posted on . Adults with overweight or obesity, but not type 2 diabetes, lost 14.9% of their body weight after 46 weeks of ...

Compared with alendronate, teriparatide was associated with significantly greater pain reduction and better quality of life among postmenopausal women with osteoporosis. Teriparatide has a favorable ...

Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 2008;168:826-831. Data from the Group Health Atrial ...

Romosozumab plus alendronate vs alendronate alone was associated with improved lumbar spine BMD among postmenopausal women with T2D and osteoporosis. Romosozumab followed by alendronate treatment ...

In postmenopausal women with osteoporosis, prior fracture, and type 2 diabetes, 12 months of romosozumab significantly improved bone strength when combined with alendronate, compared with alendronate ...

Please provide your email address to receive an email when new articles are posted on . “Glucocorticoids are the mainstay of treatment of autoimmune inflammatory diseases, but it is also the leading ...

Statin pills for patient with high cholesterol Decrease in bone mass is common in the first 6 to 12 months after kidney transplantation. Long-term use of alendronate, a bisphosphonate, may slow bone ...

Alendronate is frequently used to treat postmenopausal osteoporosis; however, the effects of long-term treatment on BMD, bone turnover, and fracture risk remain poorly characterized. The Fracture ...

New data from the extension study of the original Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) trial support earlier suggestions that treatment with an osteoanabolic agent followed ...

Alendronate and teriparatide both improve BMD in osteoporotic patients, and it seems logical that combination therapy with both agents would have a higher efficacy than either of them alone. When this ...

Romosozumab is a monoclonal antibody that binds to and inhibits sclerostin, increases bone formation, and decreases bone resorption. We enrolled 4093 postmenopausal women with osteoporosis and a ...

Radius Health announced new data from the ACTIVExtend study evaluating fracture risk reductions in postmenopausal women receiving Tymlos (abaloparatide) injection. The full findings were presented at ...